Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 15Withdrawn 2Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 1127Neoplasms 982Carcinoma, Non-Small-Cell Lung 900Prostatic Neoplasms 594Neoplasm Metastasis 528Leukemia, Myeloid, Acute 513Colorectal Neoplasms 491Lung Neoplasms 487Melanoma 485Multiple Myeloma 477Pancreatic Neoplasms 385Lymphoma 369Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 346Leukemia 339Leukemia, Lymphocytic, Chronic, B-Cell 321Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 273Carcinoma, Hepatocellular 261Glioblastoma 249Lymphoma, Large B-Cell, Diffuse 244Myelodysplastic Syndromes 242Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Breakthrough Pain × Clear all
NCT01651910 2023-05-31

The Cancer Pain and Unmet Needs Study

University of Surrey

Terminated
162 enrolled

Cancer Pain, Neoplasms, Breakthrough Pain

NCT00842829 2012-10-01

Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 4 Terminated
330 enrolled 32 charts

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡